Eton Pharmaceuticals Inc (ETON NASDAQ) stock market data APIs
$14.3338
-0.32(-2.2%)
as of March 24, 2025
Eton Pharmaceuticals Inc Financial Data Overview
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Prev. Close
14.6502
Open
14.3338
High
15.0163
Low
14.2036
52 wk Range
3.03-18.405
Market Cap
237 M
Shares Outstanding
25 836 K
Revenue
31 381 K
EPS
0.0236
Beta
1.257
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eton Pharmaceuticals Inc data using free add-ons & libraries
Get Eton Pharmaceuticals Inc Fundamental Data
Eton Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 31 381 K
- EBITDA: -5 314 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eton Pharmaceuticals Inc News
New
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarte...
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
- Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study - - Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14...
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commerci...
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients – – $0 co-pay for all eligible patients and best-in-class patient support service...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
